Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 16 to 30 of 79 results for vitamin d

  1. Dietary supplements:- Should people with coeliac disease be offered calcium and vitamin D supplements for a specific time period soon after their initial diagnosis?

    supplements:- Should people with coeliac disease be offered calcium and vitamin D supplements for a specific time period soon after...

    Research recommendation
    Published
    13 October 2015

  2. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    NG191/19 Question What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?...

    Research recommendation
    Published
    14 July 2022

  3. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory

    Research recommendation
    Published
    9 June 2015

  4. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

    COVID-19 rapid guideline
    Last updated
    8 May 2024

    Sections for NG191

  5. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

    Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.

    Technology appraisal guidance
    Published
    24 January 2007
    View recommendations

    Sections for TA117

  6. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

    Technology appraisal guidance
    Last updated
    7 February 2018
    View recommendations

    Sections for TA160

  7. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

    NICE guideline
    Last updated
    24 November 2021
    View recommendations

    Sections for NG203

  8. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

    Technology appraisal guidance
    Last updated
    7 February 2018
    View recommendations

    Sections for TA161

  9. How cost effective are preventive approaches to vitamin D deficiency among all at-risk groups, compared with the cost of testing and treatment? This should include a comparison of universal provision of free supplements with the provision of low or standard cost supplements for different at-risk groups. (If there is any new legislation allowing for the sale of Healthy Start supplements, this would provide an opportunity to test this question.)

    PH56/2 Question How cost effective are preventive approaches to vitamin D deficiency among all at-risk groups, compared with the cost of...

    Research recommendation
    Published
    9 June 2015

  10. How effective and cost effective are interventions to increase vitamin D access, uptake, adherence or status among identified at-risk groups? Does effectiveness vary by age, gender, ethnicity, socioeconomic or other specific population characteristics (such as depression or a disability)? The following could be considered: - availability and uptake of supplements (including the impact of the cost of supplements) - type of supplements provided and how that impacts on adherence - knowledge and attitudes (of both the public and health and social care practitioners).

    Question How effective and cost effective are interventions to increase vitamin D access, uptake, adherence or status among identified...

    Research recommendation
    Published
    9 June 2015

  11. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

    Clinical guideline
    Last updated
    1 September 2017
    View recommendations

    Sections for CG153

  12. Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)

    This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.

    NICE guideline
    Published
    23 May 2019
    View recommendations

    Sections for NG132

  13. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    explanatory notes(if applicable) Measuring vitamin D No evidence was available on measuring vitamin D to assess primary...

    Research recommendation
    Published
    25 October 2019

  14. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Evidence summary: COVID-19 rapid summary
    Published
    29 June 2020

  15. What types of information provision, including mass-media campaigns, are effective and cost effective in preventing skin cancer in the UK? What factors influence effectiveness and cost effectiveness? •Does effectiveness and cost effectiveness vary for different population groups? (Groups could be defined by gender, age, race/ethnicity, socioeconomic status or other characteristics such as lifestyle and at-risk behaviours.) • What impact do they have on knowledge, attitudes, awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors that aid or hinder the success of these interventions or campaigns, including for different population groups? In particular, how does changing attitudes to sunbathing and tanning – and perceptions of the risk of skin cancer –influence success? Do attitudes vary for different population groups?

    awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors...

    Research recommendation
    Published
    9 June 2015